Bristol-Myers (BMY -0.7%) makes a late-breaking presentation at the American Association for the...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers (BMY -0.7%) makes a late-breaking presentation at the American Association for the Study of Liver Diseases congress in Boston today, announcing positive interim results from Phase IIb studies combining its investigational compound Peginterferon lambda-1a with antivirals daclatasvir and ribavirin. The study showed the combination achieved high rates of sustained virologic response in targeting Hepatitis C, noting the data supports further study.